- General reference
- Symptoms and Signs
- Key Points
- Poststreptococcal Reactive Arthritis
- Resources In This Article
- Drugs Mentioned In This Article
Rheumatic fever is a nonsuppurative, acute inflammatory complication of group A streptococcal pharyngeal infection, causing combinations of arthritis, carditis, subcutaneous nodules, erythema marginatum, and chorea. Diagnosis is based on applying the modified Jones criteria to information gleaned from history, examination, and laboratory testing. Treatment includes aspirin or other NSAIDs, corticosteroids during severe carditis, and antimicrobials to eradicate residual streptococcal infection and prevent reinfection.
A first episode of acute rheumatic fever (ARF) can occur at any age but occurs most often between 5 yr and 15 yr, which are the peak years of age for streptococcal pharyngitis. ARF is uncommon before 3 yr and after 21 yr. However, preceding symptomatic pharyngitis is recognized in only about two thirds of patients with ARF.
Worldwide, incidence is 19/100,000 (range, 5 to 51/100,000), with lowest rates (< 10/100,000) in North America and Western Europe and highest rates (> 10/100,000) in Eastern Europe, the Middle East, Asia, Africa, Australia, and New Zealand. The attack rate (percentage of patients with untreated group A streptococcal pharyngitis who develop ARF) varies from < 1.0 to 3.0%. Higher attack rates occur with certain streptococcal M protein serotypes and a stronger host immune response (likely resulting from as-yet-uncharacterized genetic tendencies).
In patients with a prior episode of ARF, the rate of recurrence of ARF in untreated GAS pharyngitis approaches 50%, underscoring the importance of long-term antistreptococcal prophylaxis. Incidence has declined in most developed countries but remains high in less developed parts of the world, especially parts with aboriginal or native populations, such as Alaskan Native, Canadian Inuit, Native American, Australian Aboriginal, and Maori New Zealander, where incidence is as high as 50 to 250/100,000. However, the continued occurrence in the US of local outbreaks of ARF suggest that more rheumatogenic strains of streptococci are still present in the US.
The prevalence of chronic rheumatic heart disease is uncertain because criteria are not standardized and autopsy is not done routinely, but it is estimated that worldwide there are ≥ 33 million patients with rheumatic heart disease, resulting in about 300,000 deaths annually (1).
Group A streptococcal (GAS) pharyngitis is the etiologic precursor of acute rheumatic fever, but host and environmental factors are important. GAS M proteins share epitopes (antigenic-determinant sites that are recognized by antibodies) with proteins found in synovium, heart muscle, and heart valve, suggesting that molecular mimicry by GAS antigens from rheumatogenic strains contributes to the arthritis, carditis, and valvular damage. Genetic host risk factors include the D8/17 B-cell antigen and certain class II histocompatibility antigens. Undernutrition, overcrowding, and lower socioeconomic status predispose to streptococcal infections and subsequent episodes of rheumatic fever.
Remarkably, although GAS infections of both the pharynx and of other areas of the body (skin and soft-tissue structures, bones or joints, lungs, and bloodstream) may cause poststreptococcal glomerulonephritis, nonpharyngitis GAS infections do not lead to ARF. The reason for this distinct difference in complications resulting from infection by the same organism is not well understood.
The joints, heart, skin, and CNS are most often affected. Pathology varies by site.
Joint involvement manifests as nonspecific synovial inflammation, which if biopsied sometimes shows small foci resembling Aschoff bodies (granulomatous collections of leukocytes, myocytes, and interstitial collagen). Unlike the cardiac findings, however, the abnormalities of the joints are not chronic and do not leave scarring or residual abnormalities ("ARF licks the joints but bites the heart").
Cardiac involvement manifests as carditis, typically affecting the heart from the inside out, ie, valves and endocardium, then myocardium, and finally pericardium. It is sometimes followed years to decades later by chronic rheumatic heart disease, primarily manifested by valvular stenosis, but also sometimes by regurgitation, arrhythmias, and ventricular dysfunction.
In acute rheumatic fever, Aschoff bodies often develop in the myocardium and other parts of the heart. Fibrinous nonspecific pericarditis, sometimes with effusion, occurs only in patients with endocardial inflammation and usually subsides without permanent damage. Characteristic and potentially dangerous valve changes may occur. Acute interstitial valvulitis may cause valvular edema.
In chronic rheumatic heart disease, valve thickening, fusion, and retraction or other destruction of leaflets and cusps may occur, leading to stenosis or insufficiency. Similarly, chordae tendineae can shorten, thicken, or fuse, worsening regurgitation of damaged valves or causing regurgitation of an otherwise unaffected valve. Dilation of valve rings may also cause regurgitation.
Rheumatic valvular disease most commonly involves the mitral and aortic valves. The tricuspid and pulmonic valves are seldom if ever affected in isolation.
In acute rheumatic fever, the most common cardiac manifestations are
In chronic rheumatic heart disease, the most common cardiac manifestations are
Subcutaneous nodules appear indistinguishable from those of juvenile idiopathic arthritis (JIA), but biopsy shows features resembling Aschoff bodies. Erythema marginatum differs histologically from other skin lesions with similar macroscopic appearance, eg, the rash of systemic JIA, Henoch-Schönlein purpura, erythema chronicum migrans, and erythema multiforme. Perivascular neutrophilic and mononuclear infiltrates of the dermis occur.
An initial episode of symptoms of rheumatic fever occurs typically about 2 to 3 wk after the streptococcal infection. Manifestations typically involve some combination of the joints, heart, skin, and CNS (1).
Migratory polyarthritis is the most common manifestation of acute rheumatic fever, occurring in about 35 to 66% of children; it is often accompanied by fever. Migratory means the arthritis appears in one or a few joints, resolves but then appears in others, thus seeming to move from one joint to another. Occasionally monarthritis occurs in high-risk indigenous populations (eg, in Australia, India, Fiji) but very rarely in the US. Joints become extremely painful and tender; these symptoms are often out of proportion to the modest warmth and swelling present on examination (this is in contrast to the arthritis of Lyme disease, in which the examination findings tend to be more severe than the symptoms).
Ankles, knees, elbows, and wrists are usually involved. Shoulders, hips, and small joints of the hands and feet also may be involved, but almost never alone. If vertebral joints are affected, another disorder should be suspected.
Arthralgia-like symptoms may be due to nonspecific myalgia or tenodynia in the periarticular zone; tenosynovitis may develop at the site of muscle insertions. Joint pain and fever usually subside within 2 wk and seldom last > 1 mo.
Carditis can occur alone or in combination with pericardial rub, murmurs, cardiac enlargement, or heart failure. In the first episode of acute rheumatic fever, carditis occurs in about 50 to 70%. Patients may have high fever, chest pain, or both; tachycardia is common, especially during sleep. In about 50% of cases, cardiac damage (ie, persistent valve dysfunction) occurs much later.
Although the carditis of ARF is considered to be a pancarditis (involving the endocardium, myocardium, and pericardium), valvulitis is the most consistent feature of ARF, and if it is not present, the diagnosis should be reconsidered. The diagnosis of valvulitis has classically been made by auscultation of murmurs, but subclinical cases (ie, valvular dysfunction not manifested by murmurs but recognized on echocardiography and Doppler studies) may occur in up to 18% of cases of ARF.
Heart murmurs are common and, although usually evident early, may not be heard at initial examination; in such cases, repeated clinical examinations as well as echocardiography are recommended to determine the presence of carditis. Mitral regurgitation is characterized by an apical pansystolic blowing murmur radiating to the axilla. The soft diastolic blow at the left sternal border of aortic regurgitation, and the presystolic murmur of mitral stenosis, may be difficult to detect. Murmurs often persist indefinitely. If no worsening occurs during the next 2 to 3 wk, new manifestations of carditis seldom follow. ARF typically does not cause chronic, smoldering carditis. Scars left by acute valvular damage may contract and change, and secondary hemodynamic difficulties may develop in the myocardium without persistence of acute inflammation.
Pericarditis may be manifested by chest pain and a pericardial rub.
Heart failure caused by the combination of carditis and valvular dysfunction may cause dyspnea without rales, nausea and vomiting, a right upper quadrant or epigastric ache, and a hacking, nonproductive cough. Marked lethargy and fatigue may be early manifestations of heart failure.
Cutaneous and subcutaneous features are uncommon and almost never occur alone, usually developing in a patient who already has carditis, arthritis, or chorea.
Subcutaneous nodules, which occur most frequently on the extensor surfaces of large joints (eg, knees, elbows, wrists), usually coexist with arthritis and carditis. Fewer than 10% of children with acute rheumatic fever have nodules. Ordinarily, the nodules are painless and transitory and respond to treatment of joint or heart inflammation.
Erythema marginatum is a serpiginous, flat or slightly raised, nonscarring, and painless rash. Fewer than 6% of children have this rash. The rash usually appears on the trunk and proximal extremities but not the face. It sometimes lasts <1 day. Its appearance is often delayed after the inciting streptococcal infection; it may appear with or after the other manifestations of rheumatic inflammation.
Sydenham chorea occurs in about 10 to 30% of children. It may develop along with other manifestations but frequently arises after the other manifestations have subsided (often months after the acute streptococcal infection) and thus may be overlooked as an indicator of acute rheumatic fever. Onset of chorea is typically insidious and may be preceded by inappropriate laughing or crying. Chorea consists of rapid and irregular jerking movements that may begin in the hands but often becomes generalized, involving the feet and face.
Characteristic findings include fluctuating grip strength (milkmaid’s grip), tongue fasciculations or tongue darting (the tongue cannot protrude without darting in and out), facial grimacing, and explosive speech with or without tongue clucking. Associated motor symptoms include loss of fine motor control, and weakness and hypotonia (that can be severe enough to be mistaken for paralysis).
Previously undiagnosed obsessive-compulsive behavior may be unmasked in many patients.
Fever (≥ 38.5° C) and other systemic manifestations such as anorexia and malaise can be prominent but are not specific. ARF can occasionally manifest as FUO until a more identifiable sign develops. Abdominal pain and anorexia can occur because of the hepatic involvement in heart failure or because of concomitant mesenteric adenitis, and rarely the situation may resemble acute appendicitis.
1. Gewitz MH, Baltimore RS, Tani LY, et al: Revision of Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: A scientific statement from the American Heart Association. Circulation 131:1806–1818, 2015.
Diagnosis of a first episode of acute rheumatic fever is based on the modified Jones criteria (1; see Table: Modified Jones Criteria for a First Episode of Acute Rheumatic Fever (ARF)*); 2 major criteria or 1 major and 2 minor criteria are required, each along with evidence of preceding group A streptococcal infection. Sydenham chorea alone (ie, without minor criteria) fulfills diagnostic criteria if other causes of movement disorder are ruled out.
The modified Jones criteria were designed for the evaluation of acute rheumatic fever rather than for a possible recurrence. However, if patients have a reliable past history of acute rheumatic fever or rheumatic heart disease and also have documented group A streptococcal infection, the criteria may be used to establish the presence of a recurrence.
A preceding streptococcal infection is suggested by a recent history of pharyngitis and is confirmed by one or more of the following:
Recent scarlet fever is highly suggestive. Throat cultures and rapid strep antigen tests are often negative by the time ARF manifests, whereas titers of antistreptolysin O and anti-DNase B typically peak 3 to 6 wk after GAS pharyngitis. About 80% of children with ARF have a significantly elevated antistreptolysin O titer; if an anti-DNase B antibody level is also done, the percentage with confirmed GAS infection is higher, especially if acute and convalescent samples are tested.
Joint aspiration may be needed to exclude other causes of arthritis (eg, infection). The joint fluid is usually cloudy and yellow, with an elevated WBC count composed primarily of neutrophils; culture is negative. Complement levels are usually normal or slightly decreased, compared with decreased levels in other inflammatory arthritides.
ECG is done during the initial evaluation. Serum cardiac marker levels are obtained; normal cardiac troponin I levels exclude prominent myocardial damage. ECG abnormalities such as PR prolongation do not correlate with other evidence of carditis. Only 35% of children with ARF have a prolonged PR interval; higher-degree heart block may occur but is uncommon. Other ECG abnormalities may be due to pericarditis, enlargement of ventricles or atria, or arrhythmias.
Echocardiography can detect evidence of carditis even in patients without apparent murmurs and is recommended for all patients with confirmed or suspected ARF. Echocardiography is also used to detect subclinical carditis in patients with apparently isolated Sydenham chorea and to monitor the status of patients with recurrences of carditis or chronic rheumatic heart disease. However, not all echocardiographic abnormalities represent rheumatic carditis; isolated trivial valvar regurgitation or trivial pericardial effusion may be a nonspecific finding. To maintain specificity, echocardiographic and Doppler results should meet the following criteria (1) for acute rheumatic carditis:
Doppler flow criteria:
Pathologic mitral regurgitation: Must be seen in at least 2 views, and have a jet length ≥ 2 cm in at least 1 view, a peak velocity of > 3 m/sec, and a pansystolic jet in at least 1 envelope
Pathologic aortic regurgitation: Must be seen in at least 2 views, and have a jet length ≥ 1 cm in at least 1 view, a peak velocity of > 3 m/sec, and a pandiastolic jet in at least 1 envelope
Echocardiographic morphologic criteria:
Pathologic mitral valve morphologic changes include annular dilation, chordal elongation or rupture with flail leaflet, anterior (or less commonly posterior) leaflet tip prolapse, or beading/nodularity of leaflet tips.
Pathologic aortic valve morphologic changes include irregular or focal leaflet thickening, coaptation defect, restricted leaflet motion, or leaflet prolapse.
Chest x-rays are not routinely done but can detect cardiomegaly, a common manifestation of carditis in ARF.
Biopsy of a subcutaneous nodule can aid in early diagnosis, especially when other major clinical manifestations are absent.
ESR and serum CRP are sensitive but not specific. The ESR is typically > 60 mm/h. CRP is typically > 30 mg/L and often > 70 mg/L; because it rises and falls faster than ESR, a normal CRP may confirm that inflammation is resolving in a patient with prolonged ESR elevation after acute symptoms have subsided. In the absence of carditis, ESR usually returns to normal within 3 mo. Evidence of acute inflammation, including ESR, usually subsides within 5 mo in uncomplicated carditis. The WBC count reaches 12,000 to 20,000/μL and may go higher with corticosteroid therapy.
The differential diagnosis includes JIA (especially systemic JIA and, less so, polyarticular JIA), Lyme disease, reactive arthritis, arthropathy of sickle cell disease, leukemia or other cancer, SLE, embolic bacterial endocarditis, serum sickness, Kawasaki disease, drug reactions, and gonococcal arthritis. These are frequently distinguished by history or specific laboratory tests. The absence of an antecedent GAS infection, the diurnal variation of the fever, evanescent rash, and prolonged symptomatic joint inflammation usually distinguish systemic JIA from ARF.
Modified Jones Criteria for a First Episode of Acute Rheumatic Fever (ARF)*
Elevated ESR (> 60 mm/h) or C-reactive protein (> 30 mg/L)
Fever (≥ 38.5° C)
Prolonged PR interval (on ECG)§
*Diagnosis of acute rheumatic fever requires 2 major or 1 major and 2 minor manifestations and evidence of group A streptococcal infection (elevated or rising antistreptococcal antibody titer [eg, antistreptolysin O, anti-DNase B], positive throat culture, or positive rapid antigen test in a child with clinical manifestations suggestive of streptococcal pharyngitis).
†Carditis can be clinical and/or subclinical. Subclinical carditis is defined by strict echocardiographic criteria.
‡Polyarthralgia is not used for diagnosis if polyarthritis is a major criterion for the patient.
§PR interval is adjusted for age and is not used for diagnosis if carditis is a major criterion for the patient.
Adapted from Gewitz MH, Baltimore RS, Tani LY, et al: Revision of Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: A scientific statement from the American Heart Association. Circulation 131:1806–1818, 2015.
1. Gewitz MH, Baltimore RS, Tani LY, et al: Revision of Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: A scientific statement from the American Heart Association. Circulation 131:1806–1818, 2015.
Prognosis following an initial episode of acute rheumatic fever depends mostly on how severely the heart is affected, and whether there is a recurrent episode of acute rheumatic fever. Murmurs eventually disappear in about half of patients whose acute episodes were manifested by mild carditis without major cardiac enlargement or decompensation. However, many others develop chronic valvular disease, including some who recovered from the acute episode without evidence of valvular disease.
Episodes of Sydenham chorea usually last several months and resolve completely in most patients, but about one third of patients have recurrences.
Joint inflammation may take 1 mo to subside if not treated but does not lead to residual damage.
In patients with chronic valvular disease, symptoms develop and progress slowly, typically over several decades. However, once significant symptoms develop, intervention is usually necessary. In developing countries, chronic rheumatic heart disease is the cause of 25 to 45% of all cardiovascular disease.
The primary goals of rheumatic fever treatment are eradication of group A streptococcal infection, relief of acute symptoms, suppression of inflammation, and prophylaxis against future infection to prevent recurrent heart disease.
For general management, patients should limit their activities if they have symptoms of arthritis, chorea, or heart failure. In the absence of carditis, no physical restrictions are needed after the initial episode subsides. In asymptomatic patients with carditis, strict bed rest has no proven value, despite its traditional usage.
Although poststreptococcal inflammation is well developed by the time ARF is detected, a 10-day course of oral penicillin or amoxicillin, or a single injection of benzathine penicillin, is used to eradicate any lingering organisms and prevent reinfection. For specific regimens, see treatment of streptococcal pharyngitis. Antibiotic prophylaxis is continued as described below.
Aspirin controls fever and pain and should be given to all patients with arthritis and/or mild carditis. Although aspirin has been used for many decades, there are surprisingly few data from controlled trials to define the optimal dosing schedule. Most experts would give children and adolescents 15 to 25 mg/kg po qid (to a maximum daily dose of 4 to 6 g) for 2 to 4 wk and then taper the dose over another 4 wk. Symptomatic ARF responds dramatically to aspirin. If no improvement is seen after 24 to 48 h of high-dose aspirin therapy, the diagnosis of ARF should be reconsidered. Salicylate toxicity is the limiting factor to aspirin therapy and is manifested by tinnitus, headache, or hyperpnea; it may not appear until after 1 wk of therapy. Salicylate levels are measured only to manage toxicity. Enteric-coated, buffered, or complex salicylate molecules provide no advantage.
For patients with minimal to mild carditis, there are no controlled data to suggest that adding prednisone to aspirin therapy speeds resolution of illness or prevents rheumatic heart disease.
Other NSAIDs have been reported in small trials to be effective; naproxen (7.5 to 10 mg/kg po bid) is the most studied. However, other NSAIDs have few advantages over aspirin, especially in the first week of therapy when salicylism is uncommon. Acetaminophen is not effective for symptoms of acute rheumatic fever.
Prednisone 1 mg/kg po bid (up to 60 mg/day) is recommended instead of aspirin for patients with moderate to severe carditis (as judged by a combination of clinical findings, presence of cardiac enlargement, and possibly by severely abnormal echocardiography results). If inflammation is not suppressed after 2 days or for severe heart failure, an IV corticosteroid pulse of methylprednisolone succinate (30 mg/kg IV once/day, maximum 1 g/day, for 3 successive days) may be given. Oral corticosteroids typically are given for 2 to 4 wk and then tapered over another 2 to 3 wk. Aspirin should be started during the corticosteroid taper and continued for 2 to 4 wk after the corticosteroid has been stopped. Aspirin dose is the same as above. Inflammatory markers such as ESR and CRP may be used to monitor disease activity and response to treatment.
Recurrences of mild cardiac inflammation (indicated by fever or chest pain) may subside spontaneously; aspirin or corticosteroids should be resumed if recurrent symptoms last longer than a few days or if heart failure is uncontrolled by standard management (eg, diuretics, ACE inhibitors, beta-blockers, inotropic agents).
Antistreptococcal prophylaxis should be maintained continuously after the initial episode of acute rheumatic fever to prevent recurrences (see Table: Recommended Prophylaxis Against Recurrent Group A Streptococcal Infection). Antibiotics taken orally are slightly less effective as those given by injection. However, with the oral route, painful injections are avoided, and clinic visits and observation for postinjection reactions are not needed.
The optimal duration of antistreptococcal prophylaxis is uncertain. Children without carditis should receive prophylaxis for 5 yr or until age 21 (whichever is longer). The American Academy of Pediatrics recommends that patients with carditis without evidence of residual heart damage receive prophylaxis for 10 yr or until age 21 (whichever is longer). Children with carditis and evidence of residual heart damage should receive prophylaxis for > 10 yr; many experts recommend that such patients continue prophylaxis indefinitely or, alternatively, until age 40. Prophylaxis should be life long in all patients with severe valvular disease who have close contact with young children because young children have a high rate of GAS carriage.
Recommended Prophylaxis Against Recurrent Group A Streptococcal Infection
The American Heart Association no longer recommends that patients with known or suspected rheumatic valvular disease (who are not currently taking prophylactic antibiotics) take short-term antibiotic prophylaxis against bacterial endocarditis for dental or oral surgical procedures (see Infective Endocarditis : Prevention).
Rheumatic fever is a nonsuppurative, acute, inflammatory complication of group A streptococcal (GAS) pharyngeal infection occurring most often initially between age 5 yr and 15 yr.
Symptoms and signs may include migratory polyarthritis, carditis, subcutaneous nodules, erythema marginatum, and chorea.
Chronic rheumatic heart disease, particularly involving the mitral and/or aortic valves, may progress over decades and is a major cause of heart disease in the developing world.
Diagnosis of acute rheumatic fever (ARF) requires 2 major or 1 major and 2 minor manifestations (modified Jones criteria for a first episode of ARF) and evidence of GAS infection.
Give antibiotics to eliminate GAS infection, aspirin to control fever and pain caused by arthritis and mild carditis, and corticosteroids for patients with moderate to severe carditis.
Give prophylactic antistreptococcal antibiotics after the initial episode of ARF to prevent recurrences.
Poststreptococcal reactive arthritis is development of arthritis after group A streptococcal infection in patients who do not meet the criteria for acute rheumatic fever.
Poststreptococcal reactive arthritis may or may not represent an attenuated variant of acute rheumatic fever (ARF). Patients do not have symptoms or signs of the carditis common in ARF.
Compared with the arthritis of ARF, poststreptococcal reactive arthritis typically involves only 1 or 2 joints, is less migratory but more protracted, and does not respond as well or as quickly to aspirin. Other, nonrheumatic disorders causing similar symptoms (eg, Lyme arthritis, juvenile idiopathic arthritis) should be excluded.
It can be treated with other NSAIDs (eg, ibuprofen, naproxen).
Although clinical practice for secondary prevention of cardiac involvement varies greatly, it is reasonable to give antistreptococcal prophylaxis for several months to 1 yr and then to reevaluate the patient. If cardiac lesions are detected by echocardiography, long-term prophylaxis is indicated.
Drug NameSelect Trade
ibuprofenADVIL, MOTRIN IB
SulfadiazineNo US brand name